Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences is in a strong financial position with positive developments for their promising pipeline, including potential partnerships for their HSV treatment and a licensing agreement with Gilead for two drugs. These developments have increased the probability of success for their antiviral pipeline and have de-risked their financials. Their commercial strategy for HSV aims to provide a more effective and convenient option for patients, which could lead to higher revenues and potential partnerships for additional funding. Overall, the company's compelling pipeline and financial stability make it an attractive investment opportunity in the biotech sector.

Bears say

Assembly Biosciences is highly reliant on partnerships and collaboration with companies like Gilead, which increases the company's risk and dependence on the success of these partnerships. Furthermore, there are significant risks associated with the company's clinical development process, as well as potential delays in manufacturing and regulatory approval. These factors, along with the small potential market for their treatments, lead to a negative outlook on the stock.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.